Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6

M Fisher - British Journal of Diabetes, 2021 - bjd-abcd.com
Abstract SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with
Semaglutide in Subjects with Type 2 Diabetes) was a pre-licensing FDA-mandated …
被引用次数：1 相关文章

Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6

M Fisher - British Journal of Diabetes, 2021 - bjd-abcd.com
Abstract SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with
Semaglutide in Subjects with Type 2 Diabetes) was a pre-licensing FDA-mandated …

Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6

M Fisher - British Journal of Diabetes, 2021 - bjd-abcd.com
Abstract SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with
Semaglutide in Subjects with Type 2 Diabetes) was a pre-licensing FDA-mandated …
[PDF] archive.org

[PDF][PDF] Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6

M FISHER - Br J Diabetes, 2021 - scholar.archive.org
Abstract SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Longterm Outcomes with
Semaglutide in Subjects with Type 2 Diabetes) was a pre-licensing FDA-mandated …

Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6

M Fisher - British Journal of Diabetes, 2021 - bjd-abcd.com
Abstract SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with
Semaglutide in Subjects with Type 2 Diabetes) was a pre-licensing FDA-mandated …